Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects at least 18 years of age who have had allogenic hematopoietic cell transplant (HCT).~* Previously received at least 1 and not more than 5 lines of systemic therapy for cGVHD~* Receiving glucocorticoid therapy with a stable dose over the 2 weeks prior to screening;~* Have persistent cGVHD manifestations and systemic therapy is indicated~Exclusion Criteria:~* Subject has not been on a stable dose / regimen of systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis (ECP) are acceptable. Systemic investigational GVHD treatments are not permitted).~* Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.~* Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a washout of at least 28 days prior to treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 200mg qd (Type: EXPERIMENTAL): 200mg qd po.

Based on this trial design, predict the completion outcome and termination type (if applicable).